Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/CIMA-AEMPS/FORTASEC FLAS 2 MG LIOFILIZADO ORAL

Approved

STANDARD

FORTASEC FLAS 2 MG LIOFILIZADO ORAL

Mcneil Healthcare (Ireland) Limited🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jul 9, 2025
Approval ID: e8e3a20e4c34748e
Company: Mcneil Healthcare (Ireland) Limited
Type: Standard

Approval Details

Approval Id: e8e3a20e4c34748e
Drug Cima Aemps Name: FORTASEC FLAS 2 MG LIOFILIZADO ORAL
Register Number: 9091
Holder Company Name: Mcneil Healthcare (Ireland) Limited
Marketing Company Name: Difarmed S.L.U.
Authorization Date: 2025-07-09
Dosage Form: LIOFILIZADO ORAL
Dose: 2 mg
Route Of Administration: VÍA ORAL
Prescription Type: Sin Receta
Commercialized: No
Company Name: Mcneil Healthcare (Ireland) Limited

Active Ingredients

LOPERAMIDA

2 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jul 9, 2025

Approval ID

e8e3a20e4c34748e

Type

Standard

Back to CIMA-AEMPS Approvals

FORTASEC FLAS 2 MG LIOFILIZADO ORAL - CIMA-AEMPS Drug Approval Details